Repligen Stock Forecast, Price & News

Repligen (NASDAQ:RGEN) Frequently Asked Questions

Is Repligen a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen or view top-rated stocks.

What stocks does MarketBeat like better than Repligen?

Wall Street analysts have given Repligen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Repligen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Repligen.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) issued its earnings results on Monday, July, 26th. The biotechnology company reported $0.79 EPS for the quarter, topping the Zacks' consensus estimate of $0.52 by $0.27. The biotechnology company had revenue of $162.96 million for the quarter, compared to the consensus estimate of $144.24 million. Repligen had a trailing twelve-month return on equity of 9.21% and a net margin of 19.65%. The company's revenue was up 86.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.42 EPS.
View Repligen's earnings history.

How has Repligen's stock been impacted by COVID-19 (Coronavirus)?

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGEN shares have increased by 214.5% and is now trading at $286.22.
View which stocks have been most impacted by COVID-19.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share guidance of $2.710-$2.780 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.250. The company issued revenue guidance of $625 million-$645 million, compared to the consensus revenue estimate of $585.90 million.

What price target have analysts set for RGEN?

5 brokerages have issued 12-month price objectives for Repligen's stock. Their forecasts range from $240.00 to $368.00. On average, they anticipate Repligen's stock price to reach $296.60 in the next year. This suggests a possible upside of 3.6% from the stock's current price.
View analysts' price targets for Repligen or view top-rated stocks among Wall Street analysts.

Who are Repligen's key executives?

Repligen's management team includes the following people:

• Tony J. Hunt, President, Chief Executive Officer & Director
• James R. Bylund, Senior Vice President-Global Operations & IT
• Jon K. Snodgres, Chief Financial Officer
• Ralf Kuriyel, Senior Vice President-Research & Development
• Squire J. Servance, Secretary, Chief Compliance Officer & Senior VP

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Repligen's key competitors?

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of RGEN's competitors.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), The Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.91%), Price T Rowe Associates Inc. MD (3.20%), State Street Corp (2.39%), Alliancebernstein L.P. (2.31%), Conestoga Capital Advisors LLC (1.86%) and Brown Capital Management LLC (1.85%). Company insiders that own Repligen stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen.

Which institutional investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, 1832 Asset Management L.P., Bank of New York Mellon Corp, Marshall Wace LLP, Lord Abbett & CO. LLC, Bank of America Corp DE, Bank of America Corp DE, and Marshall Wace North America L.P.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr.
View insider buying and selling activity for Repligen or view top insider-selling stocks.

Which institutional investors are buying Repligen stock?

RGEN stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Macquarie Group Ltd., Brown Capital Management LLC, Alliancebernstein L.P., Perceptive Advisors LLC, State Street Corp, Baird Financial Group Inc., and Millennium Management LLC.
View insider buying and selling activity for Repligen or or view top insider-buying stocks.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $286.22.

How much money does Repligen make?

Repligen has a market capitalization of $15.71 billion and generates $366.26 million in revenue each year. The biotechnology company earns $59.93 million in net income (profit) each year or $1.65 on an earnings per share basis.

How many employees does Repligen have?

Repligen employs 1,128 workers across the globe.

Does Repligen have any subsidiaries?

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.

When was Repligen founded?

Repligen was founded in 1981.

What is Repligen's official website?

The official website for Repligen is www.repligen.com.

Where are Repligen's headquarters?

Repligen is headquartered at 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at (781) 250-0111 or via email at [email protected].